# Study of Nitazoxanide Compared to Placebo in Subjects With HBeAG-Negative Chronic Hepatitis B

> **NCT03905655** · PHASE2 · COMPLETED · sponsor: **Romark Laboratories L.C.** · enrollment: 51 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** Placebo Oral Tablet
- **DRUG:** Nitazoxanide

## Key facts

- **NCT ID:** NCT03905655
- **Lead sponsor:** Romark Laboratories L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-22
- **Primary completion:** 2021-03-10
- **Final completion:** 2021-10-11
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2023-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03905655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03905655, "Study of Nitazoxanide Compared to Placebo in Subjects With HBeAG-Negative Chronic Hepatitis B". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03905655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*